Chemotherapy in Treating Patients With Sarcoma of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients who have advanced or recurrent sarcoma of the uterus.
Drug: pegylated liposomal doxorubicin hydrochloride
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus|
|Study Start Date:||May 2000|
|Primary Completion Date:||March 2005 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Estimate the antitumor activity of doxorubicin HCl liposome in patients with recurrent or advanced uterine sarcoma. II. Determine the nature and degree of toxicity of this drug in this patient population.
OUTLINE: Patients receive doxorubicin HCl liposome IV over 1 hour. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study within 1-1.5 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005643
Show 49 Study Locations
|Study Chair:||Gregory P. Sutton, MD||Indiana University Melvin and Bren Simon Cancer Center|